CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Cryosurgical ablation of liver tumors

Policy on coverage of cryosurgical ablation (CSA) for primary or metastatic liver tumors for Blue Cross Blue Shield - Rhode Island products (Medicare Advantage and Commercial).

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyCryosurgical ablation of liver tumors

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionVerify member-specific benefits and eligibility against the subscriber agreement / Evidence of Coverage; claims for cryosurgical ablation using listed CPT codes are at risk of denial as not covered/not medically necessary.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3CPT codes listed as not covered / not medically necessary

Medicare Advantageproduct explicitly labeled as not covered

Commercialproduct explicitly labeled as not medically necessary

Coverage Determination

Coverage determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

ANY of the following

Medicare Advantage Plans: Cryosurgical ablation of either primary or metastatic tumors in the liver is not covered because the evidence is insufficient to determine the effects on health outcomes.
Commercial Products: Cryosurgical ablation of either primary or metastatic tumors in the liver is not medically necessary because the evidence is insufficient to determine the effects on health outcomes.

Provider Impact & Billing Guidance

Documentation Required

Benefits verification

Verify member-specific benefits and eligibility against the subscriber agreement / Evidence of Coverage as benefits may vary by contract.

Denial Risk

Potential denial for cryosurgical ablation of liver tumors

Claims for cryosurgical ablation of primary or metastatic liver tumors using the listed CPT codes are at risk of denial as not covered / not medically necessary per this policy.

47371
47381
47383

Clinical Background

Cryosurgical ablation (CSA) is a procedure that destroys target tissue by freezing, most often by inserting a probe through which coolant is circulated into the tumor. CSA can be performed as an open surgical technique or percutaneously or laparoscopically, typically with ultrasound guidance.

For individuals with unresectable primary hepatocellular carcinoma amenable to locoregional therapy, the evidence includes a randomized controlled trial, several nonrandomized comparative studies, and multiple noncomparative studies. Reported outcomes of interest include overall survival, disease-specific survival, and treatment-related mortality and morbidity. Although one randomized trial showed lower local tumor progression with cryoablation compared with radiofrequency ablation, there were no differences in survival outcomes and trial limitations mean findings require replication. Additional comparative evidence is needed to draw conclusions about the effectiveness of cryoablation compared with other locoregional therapies.

For individuals with unresectable liver metastases from neuroendocrine tumors or from colorectal cancer amenable to locoregional therapy, the evidence base is limited to systematic reviews, nonrandomized studies, and case series. Available randomized and comparative studies have methodological limitations and potential selection bias. Overall, the evidence is limited and inconsistent for both primary hepatocellular carcinoma and for liver metastases from neuroendocrine or colorectal cancer.

Because available studies do not demonstrate consistent benefits in key outcomes such as overall survival or disease-specific survival and because comparative data are limited and at risk of bias, the evidence is insufficient to determine the effects of CSA on health outcomes for unresectable primary hepatocellular carcinoma or for liver metastases. As a result, cryosurgical ablation of liver tumors is not covered / not medically necessary under the products addressed by this policy.